Early intensification of intrathecal chemotherapy virtually eliminates central nervous system relapse in children with acute lymphoblastic leukemia

Blood

Volumn 92, Issue 2, 1998, Pages 411-415

  Pui, Ching Hon ^a   Mahmoud, Hazem H ^a   Rivera, Gaston K ^a   Hancock, Michael L ^b   Sandlund, John T ^a   Behm, Frederick G ^a   Head, David R ^a   Relling, Mary V ^a   Ribeiro, Raul C ^b   Rubnitz, Jeffrey E ^a   Kun, Larry E ^b   Evans, William E ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; HYDROCORTISONE; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; BRAIN LEUKEMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CEREBROSPINAL FLUID ANALYSIS; CHILD; CHILDHOOD LEUKEMIA; HUMAN; INTRATHECAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SKULL IRRADIATION;

EID: 0032528447     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v92.2.411     Document Type: Article

References (31)

1. Pui C-H: Childhood leukemias. N Engl J Med 332:1618,1995
2. Pui C-H, Simone JV, Hancock ML, Evans WE, Williams DL, Bowman WP, Dahl GV, Dodge RK, Ochs J, Abromowitch M, Rivera GK: Impact of three methods of treatment intensification on acute lymphoblastic leukemia in children: Long-term results of St. Jude Total Therapy Study X. Leukemia 6:150,1992
3. Pullen J, Boyett J, Shuster J, Crist W, Land V, Frankel L, Lyer R, Backstrom L, van Eys J, Harris M, Ravindranath Y, Sullivan M: Extended triple intrathecal chemotherapy trial for prevention of CNS relapse in good-risk and poor-risk patients with B-progenitor acute lymphoblastic leukemia: A Pediatrie Oncology Group Study. J Clin Oncol 11:839,1993
4. Gelber RD, Sallan SE, Cohen HJ, Donnelly M, Dalton V, Tobia F, Clavell LA, Tarbell NJ: Central nervous system treatment in childhood acute lymphoblastic leukemia. Long-term follow-up of patients diagnosed between 1973 and 1985. Cancer 72:261, 1993
5. Mahmoud HH, Rivera GK, Hancock ML, Krance RA, Kun LE, Behm FG, Ribeiro RC, Sandlund JT, Crist WM, Pui C-H: Low leukocyte counts with blast cells in cerebrospinal fluid of children with newly diagnosed acute lymphoblastic leukemia. N Engl J Med 329:314, 1993
6. Tubergen DG, Gilchrist GS, O'Brien RT, Coccia PF, Sather HN, Waskerwitz MJ, Hammond GD: Prevention of CNS disease in intermediate-risk acute lymphoblastic leukemia: Comparison of cranial radiation and intrathecal methotrexate and the importance of systemic therapy: A Childrens Cancer Group Report. J Clin Oncol 11:520, 1993
7. Lauer S, Shuster J, Kirchner P, Kiefer G, Pullen J, Camilla B, Land V: Prognoslic significance of cerebrospinal fluid (CSF) lymphoblasts (LB) at diagnosis (dx) in children with acute lymphoblastic leukemia (ALL). Proc Am Soc Clin Oncol 13:317,1994
8. Camitta B, Mahoney D, Leventhal B, Lauer SJ, Shuster JJ, Adair S, Civin C, Munoz L, Steuber P, Strother D, Kamen BA: Intensive intravenous methotrexate and mercaptopurine treatment of higher-risk non-T, non-B acute lymphocytic leukemia: A Pediatrie Oncology Group study. J Clin Oncol 12:1383,1994
9. Pinkel D, Woo S : Prevention and treatment of meningeal leukemia in children. Blood 84:355,1994
10. Conter V, Aricò M, Valsecchi MG, Rizzari C, Test! AM, Messina C, Mori PG, Miniero R, Colella R, Basso G, Rondelli R, Pession A, Masera G for the Associazione Italiana di Ematologia ed Oncologia Pediatrica: Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Miinster-based intensive chemotherapy. J Clin Oncol 13:2497,1995
11. Chessells JM, Bailey C, Richards SM, for the Medical Research Council Working Party on Childhood Leukaemia: Intensification of treatment and survival in all children with lymphoblastic leukaemia: Results of UK Medical Research Council trial UKALL X. Lancet 345:143,1995
12. Winick N, Shuster JJ, Bowman WP, Borowitz M, Farrow A, Jacaruso D, Buchanan GR, Kamen BA: Intensive oral methotrexate protects against lymphoid marrow relapse in childhood B-precursor acute lymphoblastic leukemia. J Clin Oncol 4:2803,1996
13. Pui C-H, Crist WM: Biology and treatment of acute lymphoblastic leukemia. J Pediatr 124:491,1994
14. Hasle H, Helgestad J, Christensen JK, Jacobsen BB, Kamper J: Prolonged intrathecal chemotherapy replacing cranial irradiation in high-risk acute lymphatic leukaemia: Long-term follow up with cerebral computed tomography scans and endocrinological studies. Eur J Pediatr 154:24,1995
15. Corner V, Schrappe M, Aricò M, Reiter A, Rizzari C, Dördelmann, Valsecchi MG, Zimmerman M, Ludwig W-D, Basso G, Masera G, Riehm H for the Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Münster Groups: Role of cranial radiotherapy for childhood T-cell acute lymphoblastic leukemia with high WBC count and good response to prednisone. J Clin Oncol 15:2786,1997
16. Nachman J, Sather HN, Cherlow JM, Sensel MG, Gaynon PS, Lukens JN, Wolff L, Trigg ME: Response of children with high-risk acute lymphoblastic leukemia treated with and without cranial irradiation: A report from the Children's Cancer Group. J Clin Oncol 16:920, 1998
17. Pui C-H, Relling MV, Behm FG, Hancock ML, Boyett JM, Raimondi SC, Krance RA, Mahmoud HH, Ribeiro RC, Sandlund JT, Head DR, Evans WE, Crist WM, Rivera GK: L-asparaginase may potentiate the leukemogenic effect of the epipodophyllotoxins. Leukemia 9:1680,1995
18. Pui C-H, Behm FG, Crist WM: Clinical and biologic relevance of immunologie marker studies in childhood acute lymphoblastic leukemia. Blood 82:343,1993
19. Synold TW, Relling MV, Boyett JM, Rivera GK, Sandlund JT, Mahmoud H, Crist WM, Pui C-H, Evans WE: Blast cell methotrexatepolyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia. J Clin Invest 94:1996,1994
20. Bleyer WA: Clinical pharmacology of intrathecal methotrexate. II. An improved dosage regimen derived from age-related pharmacokinetics. Cancer Treat Rep 61:1419,1977
21. Kalbfleisch JD, Prentice RL: The Statistical Analysis of Failure Time Data. New York, NY, Wiley, 1980, p 163
22. Gray RJ: A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141, 1988
23. Gaynon PS, Steinherz PG, Bleyer WA, Abiin AR, Albo VC, Finklestein JZ, Grossman NJ, Novak LJ, Pyesmany AF, Reaman GH, Chappell RJ, Sather HN, Hammond GD: Improved therapy for children with acute lymphoblastic leukemia and unfavorable presenting features: A follow-up report of the Childrens Cancer Group Study CCG-106. J ' Clin Oncol 11:2234, 1993
24. Schorin MA, Blattner S, Gelber RD, Tarbell NJ, Donnelly M, Dalton V, Cohen HJ, Sallan SE: Treatment of childhood acute lymphoblastic leukemia: Results of Dana-Farber Cancer Institute/Children's Hospital Acute Lymphoblastic Leukemia Consortium Protocol 85-01. J Clin Oncol 12:740, 1994
25. Reiter A, Schrappe M, Ludwig W-D, Hiddemann W, Sauter S, Henze G, Zimmermann M, Lampert F, Havers W, Niethammer D, Odenwald E, Ritter J, Mann G, Weite K, Gadner H, Riehm H: Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood 84:3122,1994
26. Nachman J, Sather HN, Gaynon PS, Lukens JN, Wolff L, Trigg ME: Augmented Berlin-Frankfurt-Munster therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy for children and adolescents with acute lymphoblastic leukemia and unfavorable presenting features: A report from the children's cancer group. J Clin Oncol 15:2222, 1997
27. Balis FM, Lester CM, Chrousos GP, Heideman RL, Poplack DG: Differences in cerebrospinal fluid penetration of corticosteroids: Pos-sible relationship to the prevention of meningeal leukemia. J Clin Oncol 5:202,1987
28. Veerman AJP, Hählen K, Kamps WA, Van Leemven EF, De Vaan GAM, Solbu G, Suciu S, Van Wering ER, Van der Does-Van den Berg A: High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukemia: Results of protocol ALL VI from the Dutch Childhood Leukemia Study Group. J Clin Oncol 14:911,1996
29. Cherlow JM, Sather H, Steinherz P, Gaynon P, Tubergen D, Trigg M, Novak L, BleyerWA: Craniospinal irradiation for acute lymphoblastic leukemia with central nervous system disease at diagnosis: A report from the Children's Cancer Group. Int J Rad Oncol Biol Phys 36:19, 1996
30. Homans AC, Barker BE, Forman EN, Cornell CJ, Dickerman JD, Truman JT: Immunophenotypic characteristics of cerebrospinal fluid cells in children with acute lymphoblastic leukemia at diagnosis. Blood 76:1807, 1990
31. Hooijkaas H, Hählen K, Adriaansen HJ, Dekker I, van Zanen GE, van Dongen JJM: Terminal deoxynucleotidyl transferase (TdT)-positive cells in cerebrospinal fluid and development of overt CNS leukemia: A 5-year follow-up study in 113 children with a TdT-positive leukemia or non-Hodgkin's lymphoma. Blood 74:416,1989